Synergy Pharmaceuticals Inc. ( SGYP ) recently
initiated a phase Ib study on its inflammatory bowel disease (IBD)
candidate, SP-333. SP-333, a guanylate cyclase C (GC-C) agonist, is
being developed for the treatment of IBD including ulcerative
Synergy Pharma expects to enroll 64 healthy adult volunteers for
the phase I study. Synergy Pharma will be evaluating the safety
profile of SP-333 in the placebo-controlled, dose-escalating,
In Dec 2012, the company completed a phase I
single-ascending-dose clinical study on SP-333. SP-333 displayed
potent anti-inflammatory activity in animal studies of colitis. The
candidate showed a novel mechanism-of-action during the study,
which could bring a new dimension to the treatment of
The company mentioned in its press release that more than a half
million people in the US live with UC.
Synergy Pharma primarily develops drugs for the treatment of
gastrointestinal (GI) disorders and diseases. The company's lead
candidate, plecanatide, is being developed for GI disorders.
The company is developing plecanatide for the treatment of
constipation-predominant irritable bowel syndrome (IBS-C). The
company initiated a phase IIb study in IBS-C patients last month.
Currently the GI inflammatory disease market has companies like
AstraZeneca ( AZN ).
Synergy Pharma was in the news recently as its stockholders
approved Synergy Pharma's merger with Callisto Pharmaceuticals Inc.
The merger between the companies closed on Jan 17, 2013.
Synergy Pharma currently carries a Zacks Rank #3 (Hold).
However, other pharma stocks such as ArQule Inc. (
ARQL ) and
BioCryst Pharmaceuticals, Inc. ( BCRX ) carry a Zacks
Rank #2 (Buy).ARQULE INC (ARQL): Free Stock Analysis ReportASTRAZENECA PLC (AZN): Free Stock Analysis
ReportBIOCRYST PHARMA (BCRX): Free Stock Analysis
ReportSYNERGY PHARMAC (SGYP): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment